Prof. Ivan perry
1 Design of Dose Response Clinical Trials Boston Chapter of ASA April 10, 2006 Naitee Ting, Pfizer Global R&D.
Clinical trials for product developement
NIAID BioDefense Research: Challenges, Opportunities, & Sustainability Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division.
FDA IND Review: Regulations and Challenges Wilson W. Bryan, M.D. FDA / CBER / OCTGT [email protected] Workshop on Cell and Gene Therapy Clinical.
Preclinical Drug Development Chris H. Takimoto, MD, PhD Institute for Drug Development Cancer Treatment and Research Center San Antonio Cancer Institute.
Program Goals
Endocrinologic & Metabolic Drugs Advisory Committee Meeting Fabrazyme ® (agalsidase beta) January 13, 2003 Alison Lawton Senior Vice President Regulatory.
Steph Garfield-Birkbeck Assistant Director NIHR Evaluation Trials and Studies Coordinating Centre, University of Southampton.
G.L. Drusano, M.D. Co-Director Ordway Research Institute Professor and Director
Convincing the Pharmaceutical Industry to Use Surrogates for Antibiotic Development: What is Gained and What is Lost G.L. Drusano, M.D. Co-Director Ordway.
T16 Phase I studies – Phase I units and you, a Phase I unit’s expectation – A Day in the Life of a Phase I Study Coordinator Jeffery Wong, Clinical Research.
